Isao Morii

Journal: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

Published: September 22, 2021

Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation　- Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: March 29, 2019

Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?

Journal: Cardiovascular drugs and therapy

Published: August 06, 2017

Wearing Compression Garment after Endurance Exercise Promotes Recovery of Exercise Performance.

Journal: International journal of sports medicine

Published: July 26, 2016

How Does the Physician Interpret the Patient's Narrative as It Relates to the Physical Exam?; Chest pain

Journal: Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine

Published: November 06, 2015

Letter by Suwa et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial".

Letter by Suwa et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial".

Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry.

Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry.

Klebsiella Pneumoniae Invasive Syndrome With Thoracic Aortic Pseudoaneurysm.

Klebsiella Pneumoniae Invasive Syndrome With Thoracic Aortic Pseudoaneurysm.

A collateral channel from the bronchial artery in chronic total occlusion of proximal right coronary artery.

A collateral channel from the bronchial artery in chronic total occlusion of proximal right coronary artery.

CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.

CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.

Prolonged delirium during hospitalization is associated with worse long-term and short-term outcomes in patients with acute heart failure.

Prolonged delirium during hospitalization is associated with worse long-term and short-term outcomes in patients with acute heart failure.

Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.

Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.

Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation.

Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation.

Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.

Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.

Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?

Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?

Wearing Compression Garment after Endurance Exercise Promotes Recovery of Exercise Performance.

Wearing Compression Garment after Endurance Exercise Promotes Recovery of Exercise Performance.

How Does the Physician Interpret the Patient's Narrative as It Relates to the Physical Exam?; Chest pain

How Does the Physician Interpret the Patient's Narrative as It Relates to the Physical Exam?; Chest pain

Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation　- Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.

Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation　- Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.